Background. Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. Among T. cruzi-infected individuals, only a subgroup develops severe chronic Chagas cardiomyopathy (CCC); the majority remain asymptomatic. T. cruzi displays numerous ligands for the Toll-like receptors (TLRs), which are an important component of innate immunity that lead to the transcription of proinflammatory cytokines by nuclear factor-B. Because proinflammatory cytokines play an important role in CCC, we hypothesized that single-nucleotide polymorphisms (SNPs) in the genes that encode proteins in the TLR pathway could explain differential susceptibility to CCC among T. cruzi-infected individuals.
Background. Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. Among T. cruzi-infected individuals, only a subgroup develops severe chronic Chagas cardiomyopathy (CCC); the majority remain asymptomatic. T. cruzi displays numerous ligands for the Toll-like receptors (TLRs), which are an important component of innate immunity that lead to the transcription of proinflammatory cytokines by nuclear factor-B. Because proinflammatory cytokines play an important role in CCC, we hypothesized that single-nucleotide polymorphisms (SNPs) in the genes that encode proteins in the TLR pathway could explain differential susceptibility to CCC among T. cruzi-infected individuals.
Methods. For 169 patients with CCC and 76 T. cruzi-infected, asymptomatic individuals, we analyzed SNPs by use of polymerase chain reaction-restriction fragment length polymorphism analysis for the genes TLR1, TLR2, TLR4, TLR5, TLR9, and MAL/TIRAP, which encodes an adaptor protein.
Results. Heterozygous carriers of the MAL/TIRAP variant S180L were more prevalent in the asymptomatic group (24 [32%] of 76 subjects) than in the CCC group (21 [12%] of 169) ( 2 ϭ 12.6; P ϭ .0004 [adjusted P (P c ) ϭ .0084]; odds ratio [OR] , 0.31 [95% confidence interval {CI}, 0.16 -0.60]). Subgroup analysis showed a stronger association when asymptomatic patients were compared with patients who had severe CCC (i.e., patients with left-ventricular ejection fraction 40%) ( 2 ϭ 11.3; P ϭ .0008 [P c ϭ .017]; OR, 0.22 [95% CI, 0.09 -0.56]) than when asymptomatic patients were compared with patients who had mild CCC (i.e., patients with left-ventricular ejection fraction Ͼ40%) ( 2 ϭ 7.7; P ϭ .005 [P c ϭ .11]; OR, 0.33 [95% CI, 0.15-0.73]).
Conclusion. T. cruzi-infected individuals who are heterozygous for the MAL/TIRAP S180L variant that leads to a decrease in signal transduction upon ligation of TLR2 or TLR4 to their respective ligand may have a lower risk of developing CCC.
Chagas disease is caused by the intracellular protozoan parasite Trypanosoma cruzi. This parasite causes life-threatening chronic Chagas cardiomyopathy (CCC) in nearly one-third of T. cruzi-infected individuals. The remaining two-thirds of infected individuals are asymptomatic and free from heart disorders. Chagas disease remains a major threat to human health in Latin America despite efficient control of the transmitting vector, the reduviid bug. More than 18 million people are estimated to be chronically infected with T. cruzi and ϳ200,000 new cases are reported each year [1] . After acute infection, a strong immune response holds the parasite in check, but a lowgrade parasitemia persists throughout the chronic phase.
Although the underlying mechanisms that lead to the development of CCC remain poorly understood, inflammation is well documented in its pathogenesis. The survival time of patients with severe CCC is significantly shorter than that of patients with noninflammatory cardiomyopathy [2] , which suggests that inflammation plays a significant pathogenic role. Our understanding of the innate immune system, the earliest host response to invading pathogens, has been enriched by the discovery of the Toll-like receptors (TLRs) [3] . TLRs, a family of pathogenrecognition receptors, play an important role in innate immunity by acting as sensors for invading pathogens through the recognition of distinct pathogen-associated molecular patterns. The intracellular signaling of TLRs is mediated by at least 5 adaptor proteins, including MyD88, MAL/TIRAP, TRIF, TICAM, and SARM [4] . The adaptor proteins link to the Tollinterleukin-1 (IL-1) receptor (TIR) domain of the TLR, which is located in the cytosol, and bind to downstream protein kinases that ultimately lead to the activation of transcription factors, such as nuclear factor-B (NF-B) and members of the interferon (IFN)-regulatory factor family, when TLRs sense pathogen-associated molecular patterns. The inducement of specific downstream signaling, such as promotion of the transcription of proinflammatory cytokines by NF-B, provides the host with immediate first-line defense while also shaping the acquired immune response against invading pathogens.
In humans, 10 functional TLRs have been described. TLR1, TLR2-TLR6, and TLR10 are found on the extracellular surface of cells, whereas TLR3 and TLR7-TLR9 are located intracellularly within the endosomes. The TIR domain that contains the adaptor protein (TIRAP), also known as MAL, plays an essential role in signaling mediated by TLR1, TLR2, TLR4, and/or TLR6. MAL/TIRAP is the immediate downstream adaptor for TLR2 and TLR4 and acts as a bridging adaptor protein recruiting MyD88 to TLR2 and TLR4. MAL/TIRAP-deficient mice show impaired cytokine responses and NF-B activation when stimulated with ligands for TLR2, TLR4, or TLR2 with its coreceptors TLR1 and TLR6 [5, 6] .
T. cruzi contains a variety of ligands for several TLRs. T. cruziderived glycosylphosphatidylinositol (GPI) anchors activate the NF-B pathway and induce proinflammatory cytokines in Chinese hamster cells transfected with TLR2 genes [7] . Macrophages from TLR2-deficient mice show a low response to T. cruzi-derived GPI anchors, compared with macrophages from wild-type mice [7] . TLR2 functions as a heterodimer with TLR1 or TLR6. Macrophages from TLR6-deficient mice do not respond to T. cruzi-derived GPI anchors [8] . T. cruzi-derived glycoinositolphospholipids containing ceramide (GIPL-ceramide) triggered the production of chemokines in wild-type mice, but not in TLR4-deficient mice [9] . T. cruzi-derived protein Tc52 induced the synthesis of proinflammatory cytokines through TLR2 [10] . It has also been reported that TLR2 regulates interleukin-1␤-dependent cardiomyocyte hypertrophy triggered by T. cruzi, which is an important pathogenic event [11] . The proinflammatory activity of T. cruzi DNA is mediated by TLR9 [12] . Experimental infection of mice deficient for TLR2, TLR4, TLR9, and MyD88 with T. cruzi showed an increased mortality rate and earlier death, compared with wild-type mice [13] The studies mentioned above provide evidence that the TLR pathway plays an important role in determining mortality rate and parasitemia during the acute phase of experimentally induced T. cruzi infection. However, the role of the TLR in the pathogenesis of Chagas disease remains unexplored for chronic Chagas disease in humans. Although studies involving TLRdeficient mice showed a crucial role for TLR signaling in resistance to T. cruzi infection, mice deficient for a single TLR did not show either a marked increase in susceptibility or an increase in mortality rate, which suggests that several TLRs may act synergistically to provide resistance. Indeed, mice deficient for both TLR2 and TLR9 are more susceptible to T. cruzi infection than are mice deficient for a single TLR [12] .
In humans, the fact that only a subset of T. cruzi-infected individuals develop CCC and the observation of familial aggregation of patients with CCC in CCC-endemic areas [14] suggest that host genetic factors may play a role in the underlying mechanisms of disease pathogenesis. Given the important role of the T helper 1-type inflammatory process in the pathogenesis of CCC heart lesions, it is likely that the quality and intensity of the innate response may impact disease progression. We thus hypothesized that common genetic variations in the TLR and TIRAP genes may confer differential susceptibility in T. cruzi-infected individuals, some of whom develop CCC and others of whom remain asymptomatic.
Several single-nucleotide polymorphisms (SNPs) in the TLR family influence the inflammatory pathways and are associated with susceptibility to infection [15] . Two variants in the TLR4 gene, TLR-4 D299G (rs4986790) and TLR-4 T399I (rs4986791), are associated with resistance to Legionnaires disease [16] . Heterozygosity for the TLR-2 R753Q variant (rs5743708) has been suggested to impair immune activation by Borrelia burgdorferi and to protect individuals from late-stage Lyme disease [17] . With respect to the promoter polymorphisms of TLR9, TLR9 Ϫ1237C/T (rs5743836) is reported to confer susceptibility to asthma [18] , whereas TLR9 Ϫ1486C/T (rs1870884) is associated with placental malaria [19] . The TLR1 variant I602S (rs5743618) is associated with susceptibility to inflammatory bowel disease confined to the ileum, mild malaria [20, 21] , and protection against leprosy [22] . TLR6 S249P (rs5743810) is associated with asthma [23] . The TLR5 SNP transition of a cytosine to thymidine at base pair 1174 that changes an arginine at codon 392 to a stop codon (TLR5 R392stopCodon) is associated with susceptibility to Legionnaires disease [24] . Recently, it was reported that SNPs of MAL/TIRAP are associated with infectious diseases and inflammatory bowel disease [25, 26] . It is worth noting that TLR1 and TLR6 are situated on chromosome 4p14, TLR2 on chromosome 4q31.3, TLR4 on chromosome 9q32-q33, TLR5 on chromosome 1q41-1q42, TLR9 on chromosome 3p21.3, and MAL/TIRAP on chromosome 11q24.2.
These studies suggest that the genes involved in the TLR pathway play an important role in the host defense during infection. In the present study, we investigated whether SNPs in TLR1, TLR2, TLR4, TLR5, TLR9, andMAL/TIRAP, which encodes an adaptor protein, may be associated with clinical outcomes in T. cruzi-infected individuals by conducting a case-control study. As control subjects, we used asymptomatic T. cruzi-infected individuals whose disease did not progress to CCC.
SUBJECTS, MATERIALS, AND METHODS
Subjects and study design. The 245 T. cruzi-infected individuals included in the present study were monitored at the Heart Institute (InCor) of the University of São Paulo School of Medicine. Subjects provided written informed consent in accordance with the guidelines of the hospital's internal review board. The criteria used to classify T. cruzi-infected individuals as patients with CCC or asymptomatic patients, as well as details about the subjects' characteristics, are provided elsewhere [27] . In brief, 169 T. cruzi-infected individuals were classified as patients with CCC, and the remaining 76 were classified as asymptomatic. Of the 169 patients with CCC, 93 (55%) were men (mean age [Ϯ standard deviation {SD}] , 51.4 Ϯ 12.8 years), and 76 (45%) were women (mean age [Ϯ SD], 54.5 Ϯ 10.3 years). Normal left ventricular function (left-ventricular ejection fraction [LVEF], Ͼ40%) was observed in 83 patients with CCC; 32 (39%) of these patients were men, and 51 (61%) were women. Severe ventricular dysfunction (LVEF, 40%) was observed in 75 patients with CCC; 53 (71%) of these patients were men, and 22 (29%) were women. LVEF data were not available for the remaining 11 patients. Of the 76 asymptomatic subjects, 27 (36%) were men (mean age [ϮSD], 53.4 Ϯ 7.87 years), and 49 (64%) were women (mean age [ϮSD], 56.7 Ϯ 9.74 years).
SNP genotyping. We studied the following nonsynonymous SNPs: TLR1 T1805G (I602S), TLR2 R753Q, TLR4 896A/G (D229G), TLR5 R392stopCodon, and TIRAP 975C/T (S180L). We also studied the 2 promoter SNPs of TLR9 at positions T-1237C and T-1486C. The different SNPs were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. The primers and PCR proto- (table  2) . The resulting fragments were separated by electrophoresis in either a 3% agarose gel or a 12% polyacrylamide gel. To ensure the validity of our genotyping methods, a known genotype for each SNP was used as a control. Statistical analysis. Statistical analysis was performed using Prism (version 4.0; GraphPad). Allele and genotype frequencies were calculated by direct counting. Associations, both between disease groups and a specific allele and between disease groups and genotypes, were analyzed by use of the 2-tailed 2 test; odds ratios (ORs) and 95% confidence intervals (CIs) were also calculated. Hardy-Weinberg equilibrium (HWE) was determined by comparing the observed number of different genotypes with the expected number under the HWE for the estimated allele frequency. Bonferroni corrections were applied by multiplying the P values by the number of comparisons.
RESULTS
We investigated groups of T. cruzi-infected individuals for each of the variants; the number in each group was as follows: 196 subjects were evaluated for TLR1 I602S, 240 subjects for TLR2 N753G, 239 subjects for TLR4 D229G, 241 subjects for TLR5 392stop codon, 215 subjects for TLR9 TϪ1237C, 219 subjects for TLR9 TϪ1486C, and 238 subjects for TIRAP S180L. The number in each group varies because there was not adequate DNA available to test all subjects for each genotype. Table 3 shows the frequency of the genotypes and alleles of the different SNP studied. All the SNPs were in HWE in both asymptomatic subjects and subjects with CCC, except for the MAL/TIRAP S180L variant, which deviated slightly from HWE in the CCC group (P ϭ .02). Comparison of the asymptomatic and CCC groups with respect to genotype distribution for each SNP showed a statistically significant difference only for the MAL/ TIRAP S180L variant that was assessed in 75 asymptomatic subjects and 163 subjects with CCC (2 ϫ 3 2 ϭ 12.97; P ϭ .0015) ( , whereas while the percentage of subjects homozygous for the MAL/TIRAP 180L allele was similar in both groups. The percentage of subjects heterozygous for MAL/TIRAP S180L among patients with CCC was 13% (21 of 162) compared with 32% (24 of 75) among asymptomatic patients, and this difference was highly significant (2 ϫ 2 2 ϭ 12.62; P ϭ .0004; OR, 0.31 [95% CI, 0.16 -0.60]). After adjustments for multiple testing (7 SNPs studied) and comparisons (3 genotypes studied), the difference was still significant (P c ϭ .0084 [.0004 ϫ 7 ϫ 3]). The differences between patients with CCC and asymptomatic patients with respect to allele frequencies were also statistically significant (2 ϫ 2 2 ϭ 11.49; P ϭ .0007 [P c ϭ .015]; OR, 0.39 [95% CI, 0.23-0.68]), which suggests that the TIRAP 180L allele may be associated with a lower risk of developing CCC.
We stratified the patients with CCC according to their LVEF status to determine whether the TIRAP S180L variant had any influence on severity of disease. As shown in table 3, the percentage of patients with CCC who were homozygous for the TIRAP 180S allele was similar, regardless of whether their LVEF was 40% (63 [88%] of 72) or Ͼ40% (67 [84%] of 80). Heterozygosity was slightly more common among patients with CCC who had LVEF Ͼ40% (11 [14%] of 80]) than among patients with LVEF 40% (7 [10%] of 72), but this difference did not reach statistical significance. There was also no statistically significant difference between patients with CCC who had LVEF Ͼ40% and patients with CCC who had LVEF 40% with respect to the allele frequencies of the TIRAP S180L variant, which suggests that it probably has no influence on severity of disease. Compar- (7) 6 (7) 12 (7) 5 (7) TLR5, 392 (9) 29 (9) 30 (20) NOTE. Patients were stratified according to whether they had chronic Chagas cardiomyopathy (CCC) or were asymptomatic. Patients with CCC were further stratified according to whether their left-ventricular ejection fraction (LVEF) was 40% or Ͼ40%. The n value for each variant varies because there was not adequate DNA available to test all subjects for each genotype. a LVEF data was not available for 11 patients with CCC.
ison of asymptomatic patients and patients with CCC who had LVEF 40% (i.e., heterozygous subjects vs. homozygous subjects) showed a stronger association (P ϭ . 
DISCUSSION
Despite tremendous achievements in the understanding of Chagas disease, the molecular mechanism that underlies the development of CCC still remains obscure. Interest in the relationship between host genetics and the outcome of T. cruzi infection has only taken shape in the past 2 decades. Studies of the major histocompatibility complex class I and II molecules and susceptibility to Chagas disease have been controversial [28, 29] . Recently, we described several genetic variants associated with CCC [27, 30 -32] . However, no single major locus for susceptibility to CCC has been identified, which indicates that there may be several genes involved in the pathogenesis of the disease. Indeed, susceptibility to infectious diseases seems to be highly polygenic.
Several studies have reported that common genetic variations in TLRs affect host susceptibility to infectious diseases [15] . In this study, we observed that in T. cruzi-infected individuals, heterozygosity for the MAL/TIRAP S180L variant was associated with a lower risk of developing CCC. The likelihood of developing CCC was 0.31-fold lower among T. cruzi-infected individuals heterozygous for the MAL/TIRAP S180L variant, compared with homozygous carriers of the wild-type MAL/TIRAP 180S allele.
There are several plausible ways by which the MAL/TIRAP S180L variant may explain the molecular mechanism that results in a lower risk of developing CCC among certain T. cruzi-infected individuals. Functional studies of MAL/TIRAP S180L have elegantly shown that the TIRAP variant is associated with a decrease in signal-transduction efficiency with impaired cytokine production [26] . Because the immunopathology of CCC is caused by proinflammatory cytokines after T. cruzi infection, individuals homozygous for the MAL/TIRAP wild-type allele (S180) might be expected to respond with high levels of proinflammatory cytokine expression, leading to tissue damage, whereas homozygosity for the mutated allele MAL/TIRAP 180L might be expected to lead to an immune response that is insufficient to control the infection, which in turn would result in poor clearance of the parasite. In contrast, heterozygous carriers may have an intermediate state of activation of the signaling cascade that is optimal for allowing the host to hold the parasite in check while controlling the inflammatory response, as suggested by Khor et al. [26] . Our results are in line with those in the recent report by Khor et al., which showed an association between heterozygosity for the MAL/TIRAP variant S180L and protection against the following 4 infectious diseases: invasive pneumococcal disease, bacteremia, malaria, and tuberculosis [26] ; however, some conflicting results have been reported [33] . A recent study showed that TIRAP S180L polymorphism is commonly a protective factor against the development of tuberculosis and systemic lupus erythematosus [34] .
Several T. cruzi molecules, such as GPI anchors, GIPL and GIPL-ceramide , Tc52, and T. cruzi DNA, are agonists of TLR2, TLR4, and TLR9. The inflammation elicited by TLRs needs to strike an appropriate balance, resulting in an inflammatory response suited to keeping the invading pathogens in check; otherwise, excess activation of the intracellular signaling pathways may lead to high levels of proinflammatory mediators, such as interferon-␥ (IFN-␥), tumor necrosis factor-␣ (TNF-␣), and reactive nitrogen intermediates, which can result in host tissue damage. Indeed, immunohistochemical analysis of heart tissue sample obtained during autopsies of patients with severe CCC showed the presence of TNF-␣ and IFN-␥ [35, 36] ; peripheral production of both TNF-␣ and IFN-␥ have been reported to be higher in patients with CCC than in asymptomatic subjects [36, 37] . The persistence of parasites in patients with Chagas disease might also trigger ongoing inflammation. In patients with CCC, progressive inflammatory events may lead to mononuclear cell infiltration, myocarditis associated with fibrosis, and heart dysfunction [38] . Endomyocardial biopsy studies have shown that patients with CCC who experienced heart failure were more likely to have severe myocarditis, fibrosis, and myocardial hypertrophy than were either patients who had CCC but did not experience heart failure or asymptomatic patients, which suggests a key role for myocardial inflammation [39] . All these observations support a potential role for TIRAP functional polymorphisms in the pathogenesis of CCC in susceptible T. cruziinfected individuals. Hence, the progression to overt cardiomyopathy may result from the combined effect of high levels of proinflammatory cytokine expression triggered by parasite persistence and inadequate counterregulation of these cytokines. Our results also indicated that common SNPs of TLR1, TLR2, TLR4, TLR5, and TLR9 do not represent major risk factors for the development of CCC in T. cruzi-infected individuals. The functional and genetic data of the human SNPs in the extracellular domain of TLR4 D299G and T399I, which are associated with susceptibility for other diseases [16, 17] , apparently do not play a role in genetic susceptibility to CCC. The redundancy of TLR signaling by T. cruzi (i.e., T. cruzi TLR ligands, acting on TLR2-TLR6 and 9) could potentially explain why a loss-of-function mutation in a single TLR could be devoid of pathobiological consequences. Corroborating this, mice genetically deficient for both TLR2 and TLR9 had reduced control of T. cruzi infection, compared with mice deficient for only TLR2 or only TLR9 [12] . Furthermore, these same authors and others have demonstrated that mice genetically deficient for adaptor protein MyD88 show an increased mortality rate and earlier death [40] . Likewise, a lossof-function polymorphism in 1 copy of the adaptor protein gene MAL/TIRAP may protect against progression to CCC, because this variant may be associated with a reduced T. cruzi-induced immune-inflammatory response.
The development of CCC in genetically susceptible T. cruziinfected individuals takes 10 -30 years to occur. In murine models, parasite burden during the acute phase correlates with persistence during the chronic stage [41] . Thus, it seems plausible that the complex interactions between the host and the parasite that lead to indefinite control of the parasite occur during the acute phase of infection. Compared with individuals homozygous for the wild-type allele, individuals heterozygous for the TIRAP/MAL variant are probably able to strike a proper balance between generating an inflammatory response to contain the parasite and counterregulating that response.
Our present findings suggest that genes involved in the TLR pathway may also be involved in the pathogenesis of CCC in T. cruzi-infected individuals. TLR1, TLR2, TLR4, and TLR6 interact with TIRAP for signaling. The association of the TIRAP S180L variant with protection against CCC among T. cruzi-infected individuals further provides evidence for an essential role of the TLR pathway in the pathogenesis of infectious diseases.
